Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$24.93 USD
-0.54 (-2.12%)
Updated May 13, 2024 04:00 PM ET
After-Market: $25.04 +0.11 (0.44%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.93 USD
-0.54 (-2.12%)
Updated May 13, 2024 04:00 PM ET
After-Market: $25.04 +0.11 (0.44%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Zacks News
Edwards Lifesciences' Pipeline Strong Amid Rising Expenses
by Zacks Equity Research
Edwards Lifesciences' (EW) aim at building its pipeline to fortify foothold across all operating businesses augurs well for the company. However, higher operating expenses are a concern.
Patterson Companies Dental Business Dull, Competition Rife
by Zacks Equity Research
Patterson's (PDCO) dental segment sales have been weak. The company faces stiff competition from at least 15 full-service distributors and small distributors.
Align Teams Up with Exocad to Expand in Digital Scanning
by Zacks Equity Research
Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.
Hologic (HOLX) Focuses on Breast Health, Ties Up with Clarius
by Zacks Equity Research
Hologic (HOLX) forges ahead with its efforts to strengthen hold in the high potential breast cancer screening market.
Hologic's FDA Nod for Quantra Software Boosts Breast Health
by Zacks Equity Research
Hologic (HOLX) is consistently trying to boost its Breast Health segment.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) continues to grow on innovation and product launches.
Luminex (LMNX) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Luminex (LMNX) gains from recent FDA approvals and product launches.
Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.
AmerisourceBergen to Take Over H. D. Smith for $815 Million
by Zacks Equity Research
AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.
Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind
by Zacks Equity Research
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
Teladoc, Inc. (TDOC) Jumps: Stock Rises 10.5%
by Zacks Equity Research
Teladoc, Inc. (TDOC) was a big mover last session, as the company saw its shares nearly 11/% on the day amid huge volumes.
Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG
by Zacks Equity Research
Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.
McKesson Gains From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.
Varian's Halcyon Receives Shonin Approval, Grows in Oncology
by Zacks Equity Research
Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.
Intuitive Surgical Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.
Wright Medical (WMGI) Rides on Strong Portfolio & Innovation
by Zacks Equity Research
Wright Medical (WMGI) is focused on product innovation through research and development. However, lackluster international performance of the lower extremities segment is a matter of concern.
Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes
by Zacks Equity Research
Revenues at Genomic Health (GHDX) improve year over year in Q3, driven by solid performances in the United States and internationally. However, rising operating losses continue to be a spoiler.
Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow
by Zacks Equity Research
Medtronic's (MDT) latest preliminary sales update for the second quarter of fiscal 2018 holds the market in a bleak light.
Ecolab (ECL) to Refinance $375M Worth of Notes, Reduce Debt
by Zacks Equity Research
Ecolab (ECL) plans to reduce debt by refinancing notes with a lower coupon rate.
Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength
by Zacks Equity Research
Luminex's (LMNX) collaborative agreements with several companies should help expand the adoption of its products.
Intuitive Surgical (ISRG) to Gain From Procedural Business
by Zacks Equity Research
Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.